203 related articles for article (PubMed ID: 26968792)
21. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
22. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
23. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
[TBL] [Abstract][Full Text] [Related]
24. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
25. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
26. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
27. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
28. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
30. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
31. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
[TBL] [Abstract][Full Text] [Related]
32. Palifermin: in myelotoxic therapy-induced oral mucositis.
Siddiqui MA; Wellington K
Drugs; 2005; 65(15):2139-46; discussion 2147-9. PubMed ID: 16225371
[TBL] [Abstract][Full Text] [Related]
33. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation.
Treister N; Nieder M; Baggott C; Olson E; Chen L; Dang H; Krailo M; August A; Sung L
Br J Cancer; 2017 Jan; 116(1):21-27. PubMed ID: 27875526
[TBL] [Abstract][Full Text] [Related]
34. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
Jagasia MH; Abonour R; Long GD; Bolwell BJ; Laport GG; Shore TB; Durrant S; Szer J; Chen MG; Lizambri R; Waller EK
Bone Marrow Transplant; 2012 Oct; 47(10):1350-5. PubMed ID: 22327131
[TBL] [Abstract][Full Text] [Related]
35. Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation.
CzyŻewski K; DĘbski R; Bartoszewicz N; Demidowicz E; Richert-PrzygoŃska M; ŁĘcka M; Tarasenko S; StyczyŃski J
Anticancer Res; 2020 Nov; 40(11):6531-6537. PubMed ID: 33109594
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.
Hwang WY; Koh LP; Ng HJ; Tan PH; Chuah CT; Fook SC; Chow H; Tan KW; Wong C; Tan CH; Goh YT
Bone Marrow Transplant; 2004 Jul; 34(1):51-6. PubMed ID: 15208650
[TBL] [Abstract][Full Text] [Related]
37. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
38. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
[TBL] [Abstract][Full Text] [Related]
39. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
[TBL] [Abstract][Full Text] [Related]
40. A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Sakellari I; Angelopoulou M; Tsopra O; Dervenoulas I; Tsirigotis P; Spyridonidis A; Liga M; Tsionos K; Anargyrou K; Pouli A; Anagnostopoulos A
Ann Hematol; 2015 Oct; 94(10):1733-40. PubMed ID: 26141369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]